Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Shares Issued: 2017-2025

Historic Shares Issued for Cidara Therapeutics (CDTX) over the last 7 years, with Sep 2025 value amounting to $1.5 million.

  • Cidara Therapeutics' Shares Issued rose 1517.76% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.9 million, marking a year-over-year increase of 142631.43%. This contributed to the annual value of $337.3 million for FY2024, which is 276400.00% up from last year.
  • Latest data reveals that Cidara Therapeutics reported Shares Issued of $1.5 million as of Q3 2025, which was up 4,496.97% from $33,000 recorded in Q2 2025.
  • Cidara Therapeutics' Shares Issued's 5-year high stood at $98.2 million during Q4 2024, with a 5-year trough of -$107,000 in Q3 2024.
  • Moreover, its 3-year median value for Shares Issued was $59,000 (2023), whereas its average is $11.1 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Shares Issued plummeted by 95.05% in 2022, and later skyrocketed by 166,400.00% in 2024.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Shares Issued stood at $1.4 million in 2021, then crashed by 95.05% to $71,000 in 2022, then fell by 16.90% to $59,000 in 2023, then surged by 166,400.00% to $98.2 million in 2024, then skyrocketed by 1,517.76% to $1.5 million in 2025.
  • Its Shares Issued stands at $1.5 million for Q3 2025, versus $33,000 for Q2 2025 and $127,000 for Q1 2025.